1
|
Papaleo N, Climent F, Tapia G, Luizaga L, Azcarate J, Bosch-Schips J, Muñoz-Marmol AM, Salido M, Lome-Maldonado C, Vazquez I, Colomo L. Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma. Virchows Arch 2023:10.1007/s00428-023-03584-9. [PMID: 37368083 DOI: 10.1007/s00428-023-03584-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 05/25/2023] [Accepted: 06/16/2023] [Indexed: 06/28/2023]
Abstract
Aggressive large B-cell lymphomas (aLBCL) include a heterogeneous group of lymphomas with diverse biological features. One of the approaches to the diagnosis of aLBCL is based on the identification of MYC rearrangements (MYC-R), in addition to BCL2 and BCL6 rearrangements by genetic techniques, mainly fluorescent in situ hybridization (FISH). Because of the low incidence of MYC-R, the identification of useful immunohistochemistry markers to select cases for MYC FISH testing may be useful in daily practice. In a previous work, we identified a strong association between the profile CD10 positive/LMO2 negative expression and the presence of MYC-R in aLBCL and obtained good intralaboratory reproducibility. In this study, we wanted to evaluate external reproducibility. To evaluate whether LMO2 can be a reproducible marker between observers 50 aLBCL cases were circulated among 7 hematopathologists of 5 hospitals. Fleiss' kappa index for LMO2 and MYC were 0.87 and 0.70, respectively, indicating high agreement between observers. In addition, during 2021-2022, the enrolled centers included LMO2 in their diagnostic panels to evaluate prospectively the utility of the marker, and 213 cases were analyzed. Comparing LMO2 with MYC, the group of CD10 positive cases showed higher specificity (86% vs 79%), positive predictive value (66% vs 58%), likelihood positive value (5.47 vs 3.78), and accuracy (83% vs 79%), whereas the negative predictive values remained similar (90% vs 91%). These findings place LMO2 as a useful and reproducible marker to screen MYC-R in aLBCL.
Collapse
Affiliation(s)
- Natalia Papaleo
- Department of Pathology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Barcelona, Spain
- Universitat Autonoma de Barcelona, Barcelona, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Fina Climent
- Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Gustavo Tapia
- Universitat Autonoma de Barcelona, Barcelona, Spain
- Department of Pathology, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain
| | - Luis Luizaga
- Department of Pathology, Hospital Mutua Terrassa, Terrassa, Barcelona, Spain
| | - Juan Azcarate
- Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jan Bosch-Schips
- Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Ana M Muñoz-Marmol
- Universitat Autonoma de Barcelona, Barcelona, Spain
- Department of Pathology, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain
| | - Marta Salido
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain
| | - Carmen Lome-Maldonado
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain
| | - Ivonne Vazquez
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain
| | - Luis Colomo
- Universitat Pompeu Fabra, Barcelona, Spain.
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
| |
Collapse
|
2
|
Ishikawa E, Nakamura M, Shimada K, Tanaka T, Satou A, Kohno K, Sakakibara A, Furukawa K, Yamamura T, Miyahara R, Nakamura S, Kato S, Fujishiro M. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. J Gastroenterol 2020; 55:39-50. [PMID: 31493237 DOI: 10.1007/s00535-019-01616-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2019] [Accepted: 08/19/2019] [Indexed: 02/04/2023]
Abstract
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease and the most common gastrointestinal lymphoma. The prognostic/predictive indicators among patients with gastric and intestinal DLBCL (giDLBCL) are controversial beyond their anatomical sites. We compared giDLBCL cases and investigated the clinical utility of newly emerging indicators with an emphasis on programmed cell death ligand 1 (PD-L1) expression. METHODS This retrospective study included 174 patients with primary gastric (n = 129) or intestinal (n = 45) DLBCL treated with rituximab-containing chemotherapy between 1995 and 2018. RESULTS Compared with gastric DLBCL (gDLBCL) cases, patients with intestinal DLBCL (iDLBCL) had a significantly higher rate of advanced Lugano stage (71% vs 37%, P < 0.001), perforation (13% vs. 0.8%, P = 0.001), PD-L1 expression on microenvironment immune cells (miPD-L1, 70% vs 46%, P = 0.008), CD10 positivity (47% vs 28%, P = 0.027), and CD5 positivity (9% vs 1.6%, P = 0.040). The iDLBCL patients showed significantly worse progression-free survival (PFS) and overall survival (OS) than gDLBCL cases (P = 0.0338 and P = 0.0077, respectively). PD-L1 expression on tumor cells was detected in only 3 (2%) of 174 cases with early relapse and/or an aggressive clinical course; whereas, miPD-L1-positive cases had significantly better OS than the miPD-L1-negative gDLBCL and iDLBCL cases (P = 0.0281 and P = 0.0061, respectively). Multivariate analysis revealed that miPD-L1 negativity (P = 0.030) was an independent adverse prognostic factor for OS in giDLBCL. CONCLUSIONS The anatomical site of disease did not influence outcome in giDLBCL cases treated with rituximab-containing chemotherapy; while, miPD-L1 expression had a favorable impact on the outcome.
Collapse
Affiliation(s)
- Eri Ishikawa
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Aichi, Japan. .,Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
| | - Masanao Nakamura
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Aichi, Japan
| | - Kazuyuki Shimada
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Tsutomu Tanaka
- Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Akira Satou
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
| | - Kei Kohno
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Ayako Sakakibara
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Kazuhiro Furukawa
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Aichi, Japan
| | - Takeshi Yamamura
- Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan
| | - Ryoji Miyahara
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Aichi, Japan
| | - Shigeo Nakamura
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Seiichi Kato
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Mitsuhiro Fujishiro
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Aichi, Japan
| |
Collapse
|
3
|
Aprupe L, Litjens G, Brinker TJ, van der Laak J, Grabe N. Robust and accurate quantification of biomarkers of immune cells in lung cancer micro-environment using deep convolutional neural networks. PeerJ 2019; 7:e6335. [PMID: 30993030 PMCID: PMC6462181 DOI: 10.7717/peerj.6335] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 12/23/2018] [Indexed: 01/24/2023] Open
Abstract
Recent years have seen a growing awareness of the role the immune system plays in successful cancer treatment, especially in novel therapies like immunotherapy. The characterization of the immunological composition of tumors and their micro-environment is thus becoming a necessity. In this paper we introduce a deep learning-based immune cell detection and quantification method, which is based on supervised learning, i.e., the input data for training comprises labeled images. Our approach objectively deals with staining variation and staining artifacts in immunohistochemically stained lung cancer tissue and is as precise as humans. This is evidenced by the low cell count difference to humans of 0.033 cells on average. This method, which is based on convolutional neural networks, has the potential to provide a new quantitative basis for research on immunotherapy.
Collapse
Affiliation(s)
- Lilija Aprupe
- Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BioQuant, Heidelberg University, Heidelberg, Germany.,Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
| | - Geert Litjens
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.,Steinbeis Center for Medical Systems Biology (STCMSB), Heidelberg, Germany
| | - Titus J Brinker
- Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
| | - Jeroen van der Laak
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Niels Grabe
- Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BioQuant, Heidelberg University, Heidelberg, Germany.,Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.,Steinbeis Center for Medical Systems Biology (STCMSB), Heidelberg, Germany
| |
Collapse
|
4
|
Zhang L, Tong C, Tan Y, Peng S, He Y, Wang T. Hemophagocytic lymphohistiocytosis presenting with annular erythema multiforme-like eruptions in a patient with angioimmunoblastic T cell lymphoma: A case report. Exp Ther Med 2018; 16:2060-2065. [PMID: 30186440 DOI: 10.3892/etm.2018.6420] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Accepted: 06/01/2018] [Indexed: 01/19/2023] Open
Abstract
Angioimmunoblastic T cell lymphoma (AITL)-associated hemophagocytic lymphohistiocytosis (HLH) rarely occurs with annular erythema multiforme-like rashes. The present case report describes a patient who was misdiagnosed with erythema multiforme at an early stage of the disease due to annular erythema multiforme-like eruptions. However, antihistamine treatment was ineffective. The patient progressed rapidly with high fever, hepatosplenomegaly and pharyngitis. The number of copies of Epstein-Barr virus DNA continuously increased. Accompanied by the swelling of lymph nodes, the blood cell count decreased. Further bone-marrow examination and biopsy of the lymph nodes were conducted. The patient was eventually diagnosed with AITL-associated HLH, and treated with etoposide together with cyclophosphamide, doxorubicin, vincristine and prednisolone. The patient was successfully treated with several courses of chemotherapy. In view of the fact that AITL-associated HLH with annular erythema multiforme-like rashes is relatively rare worldwide and is associated with a high mortality rate, the data on previous cases were reviewed with the hope of providing clinical bases for early diagnosis and treatment of AITL-associated HLH.
Collapse
Affiliation(s)
- Liping Zhang
- Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, P.R. China
| | - Chunguang Tong
- Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Yaqi Tan
- Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Shiguang Peng
- Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Yanling He
- Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Tianyou Wang
- Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, P.R. China
| |
Collapse
|
5
|
Keller SM, Keller BC, Grest P, Börger CT, Guscetti F. Validation of Tissue Microarrays for Immunohistochemical Analyses of Canine Lymphomas. J Vet Diagn Invest 2016; 19:652-9. [DOI: 10.1177/104063870701900606] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
In most validation studies of tissue microarrays (TMAs), a fixed number of cores with a given diameter are analyzed to determine the degree of accuracy by which the TMA represents the whole section. The statistical model described in the present study predicts this property for various combinations of 2 core sizes (0.6 mm and 1.2 mm) and different core numbers. The model was based on artificial TMA core biopsies generated from Ki-67 and active caspase-3 immunostains of 40 canine lymphoma samples. Positivity was scored on a continuous scale, and a large number of cells were analyzed with the help of semiautomated cell counting. Despite considerable differences in range and distribution of Ki-67 and active caspase-3 positivity values, the model predictions showed a high degree of agreement for both markers. Comparison of 0.6 mm and 1.2 mm cores indicated that the use of small cores necessitates inclusion of a larger number of samples but requires counting a markedly smaller number of cells. Suitability of TMAs to determine the immunophenotype of the whole section was assessed using 2 different combinations of core sizes and numbers. Both displayed a high degree of concordance with the whole section (κ0.6 = 0.79; κ1.2 = 0.91). The present study provides a basis for the use of TMAs in future high-throughput immunohistochemical investigations of selected markers in canine lymphomas. The statistical model presented can be used to determine an optimal TMA design depending on a desired accuracy.
Collapse
Affiliation(s)
- Stefan M. Keller
- From the Institute of Veterinary Pathology, Vetsuisse Faculty of Zurich, Zurich, Switzerland
| | - Barbara C. Keller
- The Bioinformatics Unit, Institute for Crop Production and Grassland Research, University of Hohenheim, Stuttgart, Germany
| | - Paula Grest
- From the Institute of Veterinary Pathology, Vetsuisse Faculty of Zurich, Zurich, Switzerland
| | - Claas T. Börger
- Department of Pathology, University Hospital of Zurich, Zurich, Switzerland
| | - Franco Guscetti
- From the Institute of Veterinary Pathology, Vetsuisse Faculty of Zurich, Zurich, Switzerland
| |
Collapse
|
6
|
Gomez-Gelvez JC, Salama ME, Perkins SL, Leavitt M, Inamdar KV. Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy. Am J Clin Pathol 2016; 145:514-23. [PMID: 27124945 DOI: 10.1093/ajcp/aqw034] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVES We evaluated the prognostic impact of cell-of-origin classification as well as intratumoral regulatory T cells (Tregs), macrophages, and microvessel density (MVD) on 115 patients (74 in the training set and 41 in the validation set) diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) and uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. METHODS The prognostic impact of Tregs, macrophages, and MVD was evaluated using FOXP3, CD68, and CD34 immunohistochemical stains, respectively. In addition, we designed a scoring system where 1 point was awarded per each adverse prognostic factor, including non-germinal center B-cell-like subtype, FOXP3 17% or more, CD68 less than 2%, and MVD less than 800 vessels/mm(2) RESULTS: Although only MVD was statistically significant on multivariate analysis, the scoring system significantly segregated patients into low- and high-risk groups. Patients having two or more adverse prognostic factors (high-risk group) demonstrated significantly worse event-free and progression-free survivals in the training set and event-free survival in the validation set. CONCLUSIONS The concomitant evaluation of cell of origin along with tumor microenvironment components identifies patients with DLBCL treated with R-CHOP chemotherapy portraying a worse prognosis.
Collapse
Affiliation(s)
- Juan C Gomez-Gelvez
- From the Department of Pathology, Henry Ford Hospital, Detroit, MI Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Mohamed E Salama
- Department of Pathology, University of Utah and ARUP Institute for Experimental Pathology, Salt Lake City, UT
| | - Sherrie L Perkins
- Department of Pathology, University of Utah and ARUP Institute for Experimental Pathology, Salt Lake City, UT
| | - Matthew Leavitt
- Department of Pathology, Intermountain Health System, Salt Lake City, UT
| | - Kedar V Inamdar
- From the Department of Pathology, Henry Ford Hospital, Detroit, MI
| |
Collapse
|
7
|
Affiliation(s)
| | | | - Randy D Gascoyne
- British Colombia Cancer Research Centre, Vancouver, British Columbia, Canada
| | | |
Collapse
|
8
|
Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol 2015; 39:141-56. [PMID: 25321327 DOI: 10.1097/pas.0000000000000328] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorder. It is hypothesized that these patients have dysregulated immune surveillance of EBV. We reviewed the biopsies of 55 patients with LYG who were referred for a prospective trial at the National Cancer Institute (1995 to 2010) and evaluated the histologic, immunohistochemical, in situ hybridization, and molecular findings of these biopsies in conjunction with clinical information. Grading of the lesions was based on morphologic features and the number of EBV-positive B cells. The median age was 46 years (M:F 2.2:1). Clinically, all patients had lung involvement (100%), with the next most common site being the central nervous system (38%). No patient had nodal or bone marrow disease. All patients had past EBV exposure by serology but with a low median EBV viral load. We reviewed 122 biopsies; the most common site was lung (73%), followed by skin/subcutaneous tissue (17%); other sites included kidney, nasal cavity, gastrointestinal tract, conjunctiva, liver, and adrenal gland. Histologically, the lesions showed angiocentricity, were rich in T cells, had large atypical B cells, and were positive for EBV. Grading was performed predominantly on the lung biopsy at diagnosis; they were distributed as follows: LYG grade 1 (30%), grade 2 (22%), and grade 3 (48%). Necrosis was seen in all grades, with a greater degree in high-grade lesions. Immunoglobulin gene rearrangement studies were performed, and a higher percentage of clonal rearrangements were seen in LYG grade 2 (50%) and grade 3 (69%) as compared with grade 1 (8%). LYG is a distinct entity that can usually be differentiated from other EBV-associated B-cell lymphoproliferative disorders on the basis of the combination of clinical presentation, histology, and EBV studies. Grading of these lesions is important because it dictates the treatment choice.
Collapse
|
9
|
Abstract
Diffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell neoplasms with considerable clinical, biologic, and pathologic diversity, in part reflecting the functional diversity of the B-cell system and multiple pathways of transformation. In recent years, the advent of new high-throughput genomic technologies has provided new insights into the biology of DLBCL, leading to the identification of distinct molecular identities and novel pathogenetic pathways. This increasing complexity had led to an expanding number of entities in the World Health Organization classification. Using a multi-modality approach, the updated 2008 classification delineated some new subgroups, including DLBCLs associated with particular age groups or specific anatomic sites, as well as two borderline categories (tumors at the interface between classical Hodgkin lymphoma and DLBCL as well as between Burkitt lymphoma and DLBCL). This article reviews the histopathologic features of the various aggressive B-cell lymphoma subtypes included in the 2008 classification, with emphasis on some of the new entities as well as areas of diagnostic challenge.
Collapse
Affiliation(s)
- Yi Xie
- Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Stefania Pittaluga
- Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Elaine S Jaffe
- Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
| |
Collapse
|
10
|
Pongpruttipan T, Sukpanichnant S, Assanasen T, Bhoopat L, Kayasut K, Kanoksil W, Wannakrairot P. Interobserver variation in classifying lymphomas among hematopathologists. Diagn Pathol 2014; 9:162. [PMID: 25146638 PMCID: PMC4159536 DOI: 10.1186/s13000-014-0162-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2014] [Accepted: 08/09/2014] [Indexed: 11/24/2022] Open
Abstract
Background Lymphomas are common malignancies that have various subtypes with many overlapping histologic, immunophenotypic and genetic features. Therefore, discordance in classifying lymphoma among pathologists may be encountered. But this issue is not well characterized. We conducted the present study to demonstrate discordances among Thai hematopathologists as well as to highlight common arguing points for classifying lymphomas. Methods The 117 lymphoma cases were randomly retrieved and individually reviewed by 7 hematopathologists, members of the “Thai Hematopathologist Group,” without knowing the original diagnoses. The consensus diagnoses were given from a discussion by all members. In each case, the diagnosis from each participant was compared with the consensus diagnosis and classified into 4 categories as follow: 1) concordance, 2) minor discordance, 3) major discordance and 4) serious discordance. Results There were approximately 11% discordances between original and consensus diagnoses. The average discordances among all pathologists according to minor, major and serious discordances were 10%, 3.5% and 0.3%, respectively. Diffuse large B-cell lymphoma had the least discordance (7%). Small biopsies had been found to increase discordances in some lymphoma subtypes. Conclusions The present study reveals some degrees of interobserver variation in classifying of lymphoma by using the 2008 WHO classification among hematopathologists. Some types of lymphomas on small biopsies were found to have a significant higher discordance rate. This study also described some common diagnostic discordances regarded as potential pitfalls in classifying lymphomas. Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_162
Collapse
Affiliation(s)
| | | | | | | | | | | | - Pongsak Wannakrairot
- Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
| |
Collapse
|
11
|
Buishand FO, Visser J, Kik M, Gröne A, Keesler RI, Briaire-de Bruijn IH, Kirpensteijn J. Evaluation of prognostic indicators using validated canine insulinoma tissue microarrays. Vet J 2014; 201:57-63. [DOI: 10.1016/j.tvjl.2014.05.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Revised: 04/15/2014] [Accepted: 05/01/2014] [Indexed: 01/28/2023]
|
12
|
Keay T, Conway CM, O'Flaherty N, Hewitt SM, Shea K, Gavrielides MA. Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer. J Pathol Inform 2013; 4:19. [PMID: 23967384 PMCID: PMC3746414 DOI: 10.4103/2153-3539.115879] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Accepted: 06/04/2013] [Indexed: 11/16/2022] Open
Abstract
Background: With the emerging role of digital imaging in pathology and the application of automated image-based algorithms to a number of quantitative tasks, there is a need to examine factors that may affect the reproducibility of results. These factors include the imaging properties of whole slide imaging (WSI) systems and their effect on the performance of quantitative tools. This manuscript examines inter-scanner and inter-algorithm variability in the assessment of the commonly used HER2/neu tissue-based biomarker for breast cancer with emphasis on the effect of algorithm training. Materials and Methods: A total of 241 regions of interest from 64 breast cancer tissue glass slides were scanned using three different whole-slide images and were analyzed using two different automated image analysis algorithms, one with preset parameters and another incorporating a procedure for objective parameter optimization. Ground truth from a panel of seven pathologists was available from a previous study. Agreement analysis was used to compare the resulting HER2/neu scores. Results: The results of our study showed that inter-scanner agreement in the assessment of HER2/neu for breast cancer in selected fields of view when analyzed with any of the two algorithms examined in this study was equal or better than the inter-observer agreement previously reported on the same set of data. Results also showed that discrepancies observed between algorithm results on data from different scanners were significantly reduced when the alternative algorithm that incorporated an objective re-training procedure was used, compared to the commercial algorithm with preset parameters. Conclusion: Our study supports the use of objective procedures for algorithm training to account for differences in image properties between WSI systems.
Collapse
Affiliation(s)
- Tyler Keay
- Division of Imaging and Applied Mathematics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
| | | | | | | | | | | |
Collapse
|
13
|
Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma. J Thorac Oncol 2013; 8:644-53. [DOI: 10.1097/jto.0b013e318287c224] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J 2013; 18:411-20. [PMID: 23006945 DOI: 10.1097/ppo.0b013e31826aee97] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Diffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell lymphomas that are clinically, pathologically, and genetically diverse, in part reflecting the functional diversity of the B-cell system. The focus in recent years has been toward incorporation of clinical features, morphology, immunohistochemistry, and ever evolving genetic data into the classification scheme. The 2008 World Health Organization classification reflects this complexity with the addition of several new entities and variants. The discovery of distinct subtypes by gene expression profiling heralded a new era with a focus on pathways of transformation as well as a promise of more targeted therapies, directed at specific pathways. Some DLBCLs exhibit unique clinical characteristics with a predilection for specific anatomic sites; the anatomic site often reflects underlying biological distinctions. Recently, the spectrum of Epstein-Barr virus (EBV)-driven B-cell proliferations in patients without iatrogenic or congenital immunosuppression has been better characterized; most of these occur in patients of advanced age and include Epstein-Barr virus (EBV)-positive large B-cell lymphoma of the elderly. Human herpesvirus 8 is involved in the pathogenesis of primary effusion lymphoma, which can present as a "solid variant." Two borderline categories were created; one deals with tumors at the interface between classic Hodgkin lymphoma and DLBCL. The second confronts the interface between Burkitt lymphoma and DLBCL, so-called "B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma" in the 2008 classification. Most cases harbor both MYC and BCL2 translocations and are highly aggressive. Another interesting entity is anaplastic lymphoma kinase-positive DLBCL, which renders itself potentially targetable by anaplastic lymphoma kinase inhibitors. Ongoing investigations at the genomic level, with both exome and whole-genome sequencing, are sure to reveal new pathways of transformation in the future.
Collapse
|
15
|
Keller B, Chen W, Gavrielides MA. Quantitative assessment and classification of tissue-based biomarker expression with color content analysis. Arch Pathol Lab Med 2012; 136:539-50. [PMID: 22540303 DOI: 10.5858/arpa.2011-0195-oa] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT The use of computer aids has been suggested as a way to reduce interobserver variability that is known to exist in the interpretation of immunohistochemical staining in pathology. Such computer aids should be automated in their usage but also they should be trained in an automated and reproducible fashion. OBJECTIVE To present a computer aid for the quantitative analysis of tissue-based biomarkers, based on color content analysis. DESIGN The developed system incorporates an automated algorithm to allow retraining based on the color properties of different training sets. The algorithm first generates a color palette containing the colors present in a training subset. Based on the palette, color histograms are derived and are used as feature vectors to a pattern recognition system, which returns an output proportional to biomarker continuous expression or a categorical classification. The method was evaluated on a database of HER2/neu digital breast cancer slides, for which expression scores from a pathologist panel were available. The system was retrained and evaluated on different transformations of the database, including compression, blurring, and changes in illumination, to examine its robustness to different imaging conditions frequently met in digital pathology. RESULTS Results showed high agreement between the results of the algorithm and the truth from the pathologist panel as well as robustness to image transformations. CONCLUSIONS The results of the study are encouraging for the potential of this method as a computer aid to assess biomarker expression in a consistent and reproducible manner.
Collapse
Affiliation(s)
- Brad Keller
- Department of Biomedical Engineering, Cornell University, Ithaca, New York, USA
| | | | | |
Collapse
|
16
|
CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. Ann Hematol 2012; 91:1897-906. [PMID: 22864685 DOI: 10.1007/s00277-012-1533-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2012] [Accepted: 07/23/2012] [Indexed: 12/20/2022]
Abstract
In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non-GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non-GCB subgroup (p = 0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99- patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p = 0.004) and 2-year OS (p = 0.003) were observed in patients with GCB/CD99+ and non-GCB/CD99- compared to the others, and the combination classification was found to be an independent prognostic factor.
Collapse
|
17
|
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3460-7. [PMID: 22665537 DOI: 10.1200/jco.2011.41.4342] [Citation(s) in RCA: 491] [Impact Index Per Article: 40.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
PURPOSE Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs. PATIENTS AND METHODS Paraffin-embedded lymphoma samples from 193 patients with de novo DLBCL who were uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were studied using immunohistochemistry for MYC, BCL2, CD10, BCL6, and MUM1/interferon regulatory factor 4, and fluorescent in situ hybridization (FISH) for MYC and BCL2. RESULTS FISH analysis identified DHL in 6% of patients, who showed the expected poor overall survival (OS; P = .002). On the basis of immunohistochemical MYC and BCL2 expression, a double-hit score (DHS) was assigned to all patients with DLBCL. The DHS-2 group, defined by high expression of both MYC and BCL2 protein, comprised 29% of the patients. DHS 2 was significantly associated with lower complete response rate (P = .004), shorter OS (P < .001), and shorter progression-free survival (PFS; P < .001). The highly significant correlation with OS and PFS was maintained in multivariate models that controlled for the International Prognostic Index and the cell-of-origin subtype (OS, P < .001; PFS, P < .001). DHS was validated in an independent cohort of 116 patients who were treated with R-CHOP. CONCLUSION The immunohistochemical DHS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP.
Collapse
Affiliation(s)
- Tina Marie Green
- Department of Pathology, Odense University Hospital, J.B. Winsløws Vej 15, DK-5000 Odense C, Denmark.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Glimelius I, Qvarnström F, Simonsson M, Ekwall A, Smedby KE, Molin D, Amini RM. Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma. Histopathology 2012; 61:26-32. [DOI: 10.1111/j.1365-2559.2012.04185.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
19
|
Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, Spector N. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012; 23:736-742. [PMID: 21602260 PMCID: PMC3331732 DOI: 10.1093/annonc/mdr157] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Revised: 03/18/2011] [Accepted: 03/22/2011] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). PATIENTS AND METHODS The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. RESULTS There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. CONCLUSION CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.
Collapse
Affiliation(s)
- D Azambuja
- Department of Hematology, Postgraduate Program in Internal Medicine, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Y Natkunam
- Department of Pathology, Stanford University School of Medicine, Stanford, USA
| | - I Biasoli
- Departments of Medicine and Pathology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - I S Lossos
- Department of Medicine, Division of Hematology-Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
| | - M W Anderson
- Department of Pathology, Stanford University School of Medicine, Stanford, USA
| | - J C Morais
- Departments of Medicine and Pathology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - N Spector
- Departments of Medicine and Pathology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
| |
Collapse
|
20
|
Lawrie CH, Ballabio E, Soilleux E, Sington J, Hatton CSR, Dirnhofer S, Tzankov A. Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. Histopathology 2012; 61:18-25. [PMID: 22372580 DOI: 10.1111/j.1365-2559.2012.04179.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIMS Although many immunohistochemical (IHC) cancer biomarkers have been identified, very few have translated into routine clinical practice, primarily because of technical and observational inconsistencies between studies. However, despite the obvious need to address such variability, very few studies have done so. METHODS AND RESULTS Using bcl-6, CD10, MUM1, GCET1 and FOXP1 antibody staining on diffuse large B-cell lymphoma cases (n = 138) as a model, we employed Cronbach α analysis to quantify interobserver and intraobserver variability between four independent observers (two per institution), scoring two tissue microarrays (TMAs) stained at both institutions using differing staining procedures. The overall concordance between all observations irrespective of staining procedure or TMA source was high (average α = 0.951), with the highest level being reached for CD10 staining (average α = 0.967) and the lowest for bcl-6 (average α = 0.924). Interslide and interinstitutional reproducibility were similarly high (average α = 0.952 and average α = 0.934, respectively). Interobserver/intrainstitutional and interobserver/interinstitutional comparisons showed lower levels of concordance (average α = 0.870 and average α = 0.877, respectively), and intraobserver/interinstitutional comparisons showed the lowest levels of concordance (average α = 0.810), particularly for bcl-6 staining (α = 0.658). CONCLUSIONS This study suggests that most variability in IHC studies between centres results from inherent limitations of the biomarkers investigated rather than procedural or observational differences.
Collapse
Affiliation(s)
- Charles H Lawrie
- Biodonostia Research Institute, San Sebastián, and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
| | | | | | | | | | | | | |
Collapse
|
21
|
Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MKM, Chen G, Cheah SL, Lee M, Liu ZW, Chen J, Zhang JX, Zhang HZ, He JH, Chen FL, Zhu XD, Huang MY, Liao DZ, Fu J, Shao Q, Cai MB, Du ZM, Yan LX, Hu CF, Ng HK, Wee JT, Qian CN, Liu Q, Ernberg I, Ye W, Adami HO, Chan AT, Zeng YX, Shao JY. Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival. J Clin Oncol 2011; 29:4516-4525. [DOI: 10.1200/jco.2010.33.7741] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
Abstract
Purpose Currently, nasopharyngeal carcinoma (NPC) prognosis evaluation is based primarily on the TNM staging system. This study aims to identify prognostic markers for NPC. Patients and Methods We detected expression of 18 biomarkers by immunohistochemistry in NPC tumors from 209 patients and evaluated the association between gene expression level and disease-specific survival (DSS). We used support vector machine (SVM) –based methods to develop a prognostic classifier for NPC (NPC-SVM classifier). Further validation of the NPC-SVM classifier was performed in an independent cohort of 1,059 patients. Results The NPC-SVM classifier integrated patient sex and the protein expression level of seven genes, including Epstein-Barr virus latency membrane protein 1, CD147, caveolin-1, phospho-P70S6 kinase, matrix metalloproteinase 11, survivin, and secreted protein acidic and rich in cysteine. The NPC-SVM classifier distinguished patients with NPC into low- and high-risk groups with significant differences in 5-year DSS in the evaluated patients (87% v 37.7%; P < .001) in the validation cohort. In multivariate analysis adjusted for age, TNM stage, and histologic subtype, the NPC-SVM classifier was an independent predictor of 5-year DSS in the evaluated patients (hazard ratio, 4.9; 95% CI, 3.0 to 7.9) in the validation cohort. Conclusion As a powerful predictor of 5-year DSS among patients with NPC, the newly developed NPC-SVM classifier based on tumor-associated biomarkers will facilitate patient counseling and individualize management of patients with NPC.
Collapse
Affiliation(s)
- Hai-Yun Wang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Bing-Yu Sun
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Zhi-Hua Zhu
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ellen T. Chang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ka-Fai To
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Jacqueline S.G. Hwang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Hao Jiang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Michael Koon-Ming Kam
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Gang Chen
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Shie-Lee Cheah
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ming Lee
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Zhi-Wei Liu
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Jing Chen
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Jia-Xing Zhang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Hui-Zhong Zhang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Jie-Hua He
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Fa-Long Chen
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Xiao-Dong Zhu
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ma-Yan Huang
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ding-Zhun Liao
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Jia Fu
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Qiong Shao
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Man-Bo Cai
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Zi-Ming Du
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Li-Xu Yan
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Chun-Fang Hu
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ho-Keung Ng
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Joseph T.S. Wee
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Chao-Nan Qian
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Qing Liu
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Ingemar Ernberg
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Weimin Ye
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Hans-Olov Adami
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Anthony T. Chan
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Yi-Xin Zeng
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| | - Jian-Yong Shao
- Hai-Yun Wang, Zhi-Hua Zhu, Jing Chen, Jia-Xing Zhang, Hui-Zhong Zhang, Jie-Hua He, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu, Qiong Shao, Man-Bo Cai, Zi-Ming Du, Li-Xu Yan, Chao-Nan Qian, Qing Liu, Yi-Xin Zeng, and Jian-Yong Shao, Sun Yat-sen University Cancer Center, Guangzhou; Bing-Yu Sun, Chinese Academy of Sciences, Hefei; Ka-Fai To, Michael Koon-Ming Kam, Ho-Keung Ng, and Anthony T. Chan, Chinese University of Hong Kong, Hong Kong; Fa-Long Chen and Xiao-Dong Zhu, Guangxi Medical University, Nanning; Hao
| |
Collapse
|
22
|
Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011; 117:4726-35. [PMID: 21385849 DOI: 10.1182/blood-2010-12-323238] [Citation(s) in RCA: 232] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
We investigated age-related EBV(+) B-cell lymphoproliferations in the Western population. The clinical features, histology, immunophenotype, EBV-encoded RNA in situ hybridization, and clonality by PCR of T-cell receptor gamma and immunoglobulin genes were categorized in 122 EBV(+) lesions as follows: (1) reactive lymphoid hyperplasia; (2) polymorphic extranodal or (3) polymorphic nodal lymphoproliferative disease (LPD); and (4) diffuse large B-cell lymphoma (DLBCL). Interphase FISH for IG and PAX5 gene rearrangements was performed on 17 cases of DLBCL. The overall median age was 75 years (range, 45-101 years; 67 men, 55 women), and 67, 79, 73, and 77 years, respectively, for groups 1 through 4. Sixteen of 21 cases of polymorphic extranodal LPD were classified as EBV(+) mucocutaneous ulcer. PCR for immunoglobulin genes was polyclonal in reactive lymphoid hyperplasia (84%) and monoclonal in 33%, 63%, and 56% of polymorphic extranodal and nodal LPD cases and DLBCL, respectively. All groups showed restricted/clonal T-cell receptor responses (27%-70%). By FISH, 19% of DLBCLs showed IGH@ rearrangements, but PAX5 was unaffected. Disease-specific 5-year survival was 100%, 93%, 57%, and 25% for groups 1-4, respectively, and 100% for patients with EBV(+) mucocutaneous ulcer. Disease volume was predictive of therapy response (P = .0002), and pathologic subtype was predictive of overall outcome (P = .001). Age-related EBV(+) B-cell LPD encompasses a wider disease spectrum than previously recognized and includes both reactive and neoplastic conditions. Reduction in the T-cell repertoire may contribute to decreased immune surveillance.
Collapse
|
23
|
Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2011; 2011:506-514. [PMID: 22160082 PMCID: PMC6329301 DOI: 10.1182/asheducation-2011.1.506] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Aggressive B-cell lymphomas are clinically and pathologically diverse and reflect multiple pathways of transformation. The 2008 World Health Organization (WHO) classification reflects this complexity with the addition of several new entities and variants. Whereas MYC translocations have long been associated with Burkitt lymphoma (BL), deregulation of MYC has been shown to occur in other aggressive B-cell lymphomas, most often as a secondary event. Lymphomas with translocations of both MYC and BCL2 are highly aggressive tumors, with a high failure rate with most treatment protocols. These "double-hit" lymphomas are now separately delineated in the WHO classification as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and BL. A MYC translocation is also found uncommonly in DLBCL, but the clinical consequences of this in the absence of a double hit are not yet fully delineated. Most recently, MYC translocations have been identified as a common secondary event in plasma cell neoplasms, seen in approximately 50% of plasmablastic lymphoma. Another area that has received recent attention is the spectrum of EBV-driven B-cell proliferations in patients without iatrogenic or congenital immunosuppression; most of these occur in patients of advanced age and include the EBV-positive large B-cell lymphomas of the elderly.
Collapse
Affiliation(s)
- Elaine S Jaffe
- Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
| | | |
Collapse
|
24
|
Syrbu SI, Cohen MB. An enhanced antigen-retrieval protocol for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues. Methods Mol Biol 2011; 717:101-10. [PMID: 21370027 DOI: 10.1007/978-1-61779-024-9_6] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Formalin is the most commonly used fixative for light microscopy because of its preservation of -morphological details. A major adverse effect of formalin fixation is formation of cross-linkages between epitopes (amino acid residues) and unrelated proteins by formaldehyde groups. The great majority of monoclonal and polyclonal antibodies used for immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded (FFPE) tissues necessitate unmasking antigens for antigen retrieval. There are currently two major antigen-retrieval procedures based on treatment of deparaffinized tissue sections with heat or, less commonly, with enzymatic digestion. The use of various antigen-retrieval solutions and heating sources does not allow standardization of IHC staining and minimalization of interlaboratory discrepancies. We developed a novel modified antigen-retrieval protocol for reversing the effect of -formalin fixation. The key feature of this protocol is treatment of deparaffinized tissue sections at reduced constant heat (97(o)C in a water bath) for 40 min in 25 mM Tris-HCl (pH 8.5), 1 mM EDTA, and 0.05% SDS (Tris-EDTA-SDS) buffer. Sections are then immunostained with primary and secondary antibodies conjugated with polymer-labeled Horse Radish Peroxidase. Compared to conventional antigen-retrieval procedures, this protocol more efficiently reverses the effect of formalin fixation of a wide variety of cellular antigens and in most instances decreases the use of primary antibody by 2-40 times, resulting in cost savings. Moreover, this protocol eliminates the need for using different antigen-retrieval methods in the laboratory, which reduces both time and labor for medical technologists.
Collapse
Affiliation(s)
- Sergei I Syrbu
- Immunopathology Laboratory, Department of Pathology, The University of Iowa, Iowa City, IA, USA.
| | | |
Collapse
|
25
|
Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010; 51:199-212. [PMID: 19925052 DOI: 10.3109/10428190903370338] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A number of biomarkers, particularly proteins that contribute to prognosis in diffuse large B cell lymphoma (DLBCL), have been identified. However, translation into accepted standards to predict survival has not yet been accomplished, primarily due to contradictory reports in the literature resulting from, among other factors, arbitrary methodologies used to set cut-off values for determining positivity. Some of these problems might be resolved by application of rational statistical methods for determination of cut-off scores. Herein, we critically address issues on in situ phenotypic prognostic tumor-related biomarkers in DLBCL with a particular and practical emphasis on tools for cut-off level determination, especially receiver operating characteristic curve analysis. Moreover, we candidly illustrate the application of these tools for efficient disease-specific survival prognostication on a tissue microarray collective of 240 primary DLBCL using the common prognostic biomarkers Bcl-2, Bcl-6, CD10, FOXP1, MUM1, and Cyclin E. Comparison of the results relative to disease-specific survival unequivocally showed the superior discriminatory power of the cut-off levels calculated by receiver operating curves and the Youden's index, compared to arbitrary cut-off values from the literature, advocating fundamental application of rational methods for determination of clinically relevant prognostic biomarkers' cut-off scores.
Collapse
|
26
|
EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34:405-17. [PMID: 20154586 DOI: 10.1097/pas.0b013e3181cf8622] [Citation(s) in RCA: 380] [Impact Index Per Article: 27.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We describe a series of Epstein Barr virus (EBV)-positive circumscribed, ulcerative lesions associated with various types of immunosuppression (IS). The study group (26 patients) comprised 10 males and 16 females, median age 77 years (range 42 to 101). IS in 9 cases included azathioprine (AZA), methotrexate (MTX) or cyclosporin-A (CyA). Seventeen patients had age-related immunosenescence. Patients presented with isolated sharply circumscribed ulcers involving oropharyngeal mucosa (16), skin (6), and gastrointestinal tract (4). Lesions were histologically characterized by a polymorphous infiltrate and atypical large B-cell blasts often with Hodgkin/Reed-Sternberg (HRS) cell-like morphology. The B cells showed strong CD30 and EBER positivity, some with reduced CD20 expression, in a background of abundant T cells. CD15 was positive in 43% of cases (10/23). The pathologic features were identical regardless of the anatomic site or cause of IS. Polymerase chain reaction revealed 39% (7/18) clonal Ig gene rearrangements with 38% (6/16) and 31% (5/16) clonal and restricted T-cell patterns, respectively. Twenty-five percent of patients (5/20) received standard chemotherapy and/or radiotherapy. Forty-five percent (9/20) regressed spontaneously with no treatment and 15% (3/20) were characterized by a relapsing and remitting course. All of the iatrogenic lesions (6/6) with available follow-up responded to reduction of IS. All patients achieved complete remission with no disease-associated deaths over a median follow-up period of 22 months (range 3 to 72). We propose EBV-positive mucocutaneous ulcer as a newly recognized clinicopathologic entity with Hodgkin-like features and a self-limited, indolent course, generally responding well to conservative management. Association with various forms of IS implies a common pathogenetic mechanism. The localized nature of the disease may be owing to a minimal and localized lapse in immunosurveillance over EBV.
Collapse
|
27
|
Sheth A, de Melo VAS, Szydlo R, Macdonald DH, Reid AG, Wagner SD. Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma. ACTA ACUST UNITED AC 2009; 194:48-52. [PMID: 19737654 DOI: 10.1016/j.cancergencyto.2009.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2009] [Revised: 05/22/2009] [Accepted: 05/24/2009] [Indexed: 10/20/2022]
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. Certain chromosomal translocations are associated with clinical outcome, but it is likely that there are both tumor suppressor genes and oncogenes that cooperate with the primary translocations. We have used the Mitelman database to compare chromosomal losses and gains of DLBCL possessing t(14;18), t(8;14), or t(3;14) with DLBCL lacking any of these translocations. The data we obtained are low resolution, but results for t(3;14) validate the methodology. In accord with the literature, loss of 6q was associated with t(3;14). Chromosomes 11, 13, and X were gained significantly in t(3;14), whereas 8p23 was lost. Cases with t(14;18) were associated with gains of chromosomes 7 and 12; cases with t(8;14) were associated with gains of chromosomes 1 and 4.
Collapse
Affiliation(s)
- Avni Sheth
- Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK
| | | | | | | | | | | |
Collapse
|
28
|
King RL, Pasha T, Roullet MR, Zhang PJ, Bagg A. IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol 2009; 40:1699-705. [PMID: 19698973 DOI: 10.1016/j.humpath.2009.05.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2009] [Revised: 04/24/2009] [Accepted: 05/05/2009] [Indexed: 11/26/2022]
Abstract
IMP-3 is a member of the insulin-like growth factor II mRNA binding protein (IMP) family of proteins that play a role in RNA trafficking and stabilization and cell growth and migration during embryogenesis but which are down-regulated in adult tissue. However, IMP-3 has recently been shown to be overexpressed in several epithelial malignancies, with increased expression correlating with aggressive behavior. To our knowledge, there is no published literature evaluating IMP-3 in lymphoid tissue. Accordingly, we immunohistochemically evaluated IMP-3 expression in normal lymphoid tissue and 141 lymphoid neoplasms. Physiologically, IMP-3 expression was restricted to germinal center B cells. Among lymphoid neoplasms, Hodgkin lymphoma demonstrated the highest percentage of positive cases (26/26, 100%) often with bright staining. Burkitt lymphoma was positive in 10 (83%) of 12 cases with moderate to bright staining. Although follicular lymphoma was also positive in a high percentage of cases (12/15, 80%), the intensity was exclusively weak to moderate. Although 22 (85%) of 26 of diffuse large B-cell lymphomas were positive for IMP-3, there was wide variability in staining intensity, which did not correlate with classification into activated B cell versus germinal center B origin. By contrast, lower proportions (8%-20%) of other non-germinal center B lymphoma subtypes were IMP-3-positive. In conclusion, although IMP-3 expression is seemingly restricted to physiologic germinal center B cells, its expression in lymphomas of germinal center B origin is less robust. However, there does appear to be some association with the latter group of lymphomas, which may prove to have diagnostic or therapeutic relevance as the biologic role of IMP-3 is further elucidated.
Collapse
Affiliation(s)
- Rebecca L King
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
| | | | | | | | | |
Collapse
|
29
|
Permuth-Wey J, Boulware D, Valkov N, Livingston S, Nicosia S, Lee JH, Sutphen R, Schildkraut J, Narod S, Parker A, Coppola D, Sellers T, Pal T. Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:28-34. [PMID: 19124477 DOI: 10.1158/1055-9965.epi-08-0713] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
INTRODUCTION Tissue microarrays (TMA) enable rapid analysis of biomarkers in large-scale studies involving archival tumor specimens, however, their utility in heterogeneous tumors such as ovarian cancer is limited. METHODS In this study, immunohistochemical analysis was done on TMAs comprised of epithelial ovarian cancer (EOC) to estimate the prevalence of loss of expression of three mismatch repair proteins. TMAs were initially created using cores sampled from the center of donor tissue blocks from 59 EOC cases. Full sections were subsequently created and levels of expression were compared between tissues sampled from the central portion versus the periphery. Follow-up analyses were done by obtaining cores from the periphery of up to five additional donor blocks per case. A linear mixed model for each protein was used to investigate differences between results from the initial and follow-up blocks. RESULTS In the original TMAs created using centrally sampled cores, loss of mismatch repair expression was noted in 17 (29%) of the 59 cases. By comparison, analyses from peripherally sampled cores revealed loss of expression in only 6 of these 17 cases. For each protein, significant differences (P < 0.05) were detected between results from the initial donor block and the majority of the follow-up blocks. CONCLUSIONS Our investigations, based on EOC, suggest that sampling variability in protein expression may result when TMAs are used. Thus, at least for EOC, it is important to preferentially sample from the periphery of tumor blocks where exposure to tissue fixatives is optimal.
Collapse
|
30
|
Borovecki A, Korać P, Nola M, Ivanković D, Jaksić B, Dominis M. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. Croat Med J 2009; 49:625-35. [PMID: 18925696 DOI: 10.3325/cmj.2008.5.625] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
AIM To define prognostic significance of B-cell differentiation genes encoding proteins and BCL2 and BCL6 gene abnormalities in diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern. METHODS In 53 patients with diffuse large B-cell lymphoma and 20 patients with follicular lymphoma grade 3 with >75% follicular growth pattern the following was performed: 1) determination of protein expression of BCL6, CD10, MUM1/IRF4, CD138, and BCL2 by immunohistochemistry; 2) subclassification into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) groups according to the results of protein expression; 3) detection of t(14;18)(q32;q21)/IgH-BCL2 and BCL6 abnormalities by fluorescent in situ hybridization in diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern as well as in GCB and ABC groups; and 4) assessment of the influence of the analyzed characteristics and clinical prognostic factors on overall survival. RESULTS Only BCL6 expression was more frequently found in follicular lymphoma grade 3 with >75% follicular growth pattern than in diffuse large B-cell lymphoma (P=0.030). There were no differences in BCL2 and BCL6 gene abnormalities between diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern. Diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients were equally distributed in GCB and ABC groups. t(14;18)(q32;q21) was more frequently recorded in GCB group, and t(14;18)(q32;q21) with BCL2 additional signals or only BCL2 and IgH additional signals in ABC group (P=0.004). The GCB and ABC groups showed no difference in BCL6 gene abnormalities. There was no overall survival difference between the diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients, however, GCB group had longer overall survival than ABC group (P=0.047). Multivariate analysis showed that BCL6, CD10, and BCL2 expression, BCL2 and BCL6 abnormalities, and International Prognostic Index were not significantly related to overall survival. CONCLUSION Diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients have very similar characteristics and their prognosis is more influenced by protein expression of B-cell differentiation stage genes than by tumor cells growth pattern, BCL2 and BCL6 abnormalities, and International Prognostic Index.
Collapse
Affiliation(s)
- Ana Borovecki
- Department of Clinical Pathology and Cytology, Merkur University Hospital, Zajceva 19, 10000 Zagreb, Croatia.
| | | | | | | | | | | |
Collapse
|
31
|
Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 2009; 27:1091-9. [PMID: 19188679 DOI: 10.1200/jco.2008.16.6991] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
PURPOSE Approximately 30% of patients with stage IB non-small-cell lung cancer (NSCLC) die within 5 years after surgery. Current staging methods are inadequate for predicting the prognosis of this particular subgroup. This study identifies prognostic markers for NSCLC. PATIENTS AND METHODS We used computer-generated random numbers to study 148 paraffin-embedded specimens for immunohistochemical analysis. We studied gene expression in paraffin-embedded specimens of lung cancer tissue from 73 randomly selected patients with stage IB NSCLC who had undergone radical surgical resection and evaluated the association between the level of expression and survival. We used support vector machines (SVM)-based methods to develop three immunomarker-SVM-based prognostic classifiers for stage IB NSCLC. For validation, we used randomly assigned specimens from 75 other patients. RESULTS We devised three immunomarker-SVM-based prognostic classifiers, including SVM1, SVM2, and SVM3, to refine prognosis of stage IB NSCLC successfully. The SVM1 model integrates age, cancer cell type, and five markers, including CD34MVD, EMA, p21ras, p21WAF1, and tissue inhibitors of metalloproteinases (TIMP) -2. The SVM2 model integrates age, cancer cell type, and 19 markers, including BCL2, caspase-9, CD34MVD, low-molecular-weight cytokeratin, high-molecular-weight cytokeratin, cyclo-oxygenase-2, EMA, HER2, matrix metalloproteinases (MMP) -2, MMP-9, p16, p21ras, p21WAF1, p27kip1, p53, TIMP-1, TIMP-2, vascular endothelial growth factor (VEGF), and beta-catenin. The SVM3 model consists of SVM1 and SVM2. The three models were independent predictors of overall survival. We validated the classifiers with data from an independent cohort of 75 patients with stage IB NSCLC. CONCLUSION The three immunomarker-SVM-based prognostic characteristics are closely associated with overall survival among patients with stage IB NSCLC.
Collapse
Affiliation(s)
- Zhi-Hua Zhu
- Department of Thoracic Oncology, Cancer Center of Sun Yat-Sen University, 651 Dongfeng Rd E, Guangzhou 510060, People's Republic of China, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lumbreras B, Porta M, Marquez S, Pollán M, Parker LA, Hernández-Aguado I. Sources of error and its control in studies on the diagnostic accuracy of “-omics” technologies. Proteomics Clin Appl 2009; 3:173-184. [DOI: 10.1002/prca.200800092] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
|
33
|
Conway C, Dobson L, O'Grady A, Kay E, Costello S, O'Shea D. Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs. Histochem Cell Biol 2008; 130:447-63. [PMID: 18679705 DOI: 10.1007/s00418-008-0480-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/05/2008] [Indexed: 01/16/2023]
Abstract
Tissue Microarrays facilitate high-throughput immuohistochemistry; however, there are key bottlenecks apparent in their analysis, particularly when conducting microscope-based manual reviews. Traditionally Tissue Microarray assessments were performed using a microscope where results were either transcribed or dictated and subsequently entered into flat-file spreadsheets. This process is labour intensive, prone to error and negates the advantages of the high-throughput Tissue Microarray format. In addition, human interpretations of staining intensity parameters are highly subjective and therefore prone to inter- and intra-observer variability. The advent of Virtual Slides has permitted the review of tissue slides across the Internet. In addition, this new technology enables the creation of software solutions to assist in the manual and automated review of Tissue Microarrays, through the use of computer aided image analysis. There are numerous academically developed and commercially available applications which assist in Tissue Microarray reviews; functionality of these systems range in complexity and application domains. The review which follows describes these systems and outlines technical considerations to be assessed when deciding on a Tissue Microarray workflow solution.
Collapse
|
34
|
Lejeune M, Jaén J, Pons L, López C, Salvadó MT, Bosch R, García M, Escrivà P, Baucells J, Cugat X, Alvaro T. Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat 2008; 212:868-78. [PMID: 18510512 DOI: 10.1111/j.1469-7580.2008.00910.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Tissue microarray technology and immunohistochemical techniques have become a routine and indispensable tool for current anatomical pathology diagnosis. However, manual quantification by eye is relatively slow and subjective, and the use of digital image analysis software to extract information of immunostained specimens is an area of ongoing research, especially when the immunohistochemical signals have different localization in the cells (nuclear, membrane, cytoplasm). To minimize critical aspects of manual quantitative data acquisition, we generated semi-automated image-processing steps for the quantification of individual stained cells with immunohistochemical staining of different subcellular location. The precision of these macros was evaluated in 196 digital colour images of different Hodgkin lymphoma biopsies stained for different nuclear (Ki67, p53), cytoplasmic (TIA-1, CD68) and membrane markers (CD4, CD8, CD56, HLA-Dr). Semi-automated counts were compared to those obtained manually by three separate observers. Paired t-tests demonstrated significant differences between intra- and inter-observer measurements, with more substantial variability when the cellular density of the digital images was > 100 positive cells/image. Overall, variability was more pronounced for intra-observer than for inter-observer comparisons, especially for cytoplasmic and membrane staining patterns (P < 0.0001 and P = 0.050). The comparison between the semi-automated and manual microscopic measurement methods indicates significantly lower variability in the results yielded by the former method. Our semi-automated computerized method eliminates the major causes of observer variability and may be considered a valid alternative to manual microscopic quantification for diagnostic, prognostic and therapeutic purposes.
Collapse
Affiliation(s)
- Marylène Lejeune
- Department of Pathology, Hospital de Tortosa Verge de la Cinta, Tortosa, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J, Wright G, Sanger WG, Pickering DL, Jain S, Horsman DE, Shen Y, Fu K, Weisenburger DD, Hans CP, Campo E, Gascoyne RD, Rosenwald A, Jaffe ES, Delabie J, Rimsza L, Ott G, Müller-Hermelink HK, Connors JM, Vose JM, McKeithan T, Staudt LM, Chan WC. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007; 21:2332-43. [PMID: 17625604 PMCID: PMC2366166 DOI: 10.1038/sj.leu.2404856] [Citation(s) in RCA: 141] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed biologically and prognostically distinct subgroups: germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal (PM) DLBCL. The BCL6 gene is often translocated and/or mutated in DLBCL. Therefore, we examined the BCL6 molecular alterations in these DLBCL subgroups, and their impact on BCL6 expression and BCL6 target gene repression. BCL6 translocations at the major breakpoint region (MBR) were detected in 25 (18.8%) of 133 DLBCL cases, with a higher frequency in the PM (33%) and ABC (24%) subgroups than in the GCB (10%) subgroup. Translocations at the alternative breakpoint region (ABR) were detected in five (6.4%) of 78 DLBCL cases, with three cases in ABC and one case each in the GCB and the unclassifiable subgroups. The translocated cases involved IgH and non-IgH partners in about equal frequency and were not associated with different levels of BCL6 mRNA and protein expression. BCL6 mutations were detected in 61% of DLBCL cases, with a significantly higher frequency in the GCB and PM subgroups (>70%) than in the ABC subgroup (44%). Exon-1 mutations were mostly observed in the GCB subgroup. The repression of known BCL6 target genes correlated with the level of BCL6 mRNA and protein expression in GCB and ABC subgroups but not with BCL6 translocation and intronic mutations. No clear inverse correlation between BCL6 expression and p53 expression was observed. Patients with higher BCL6 mRNA or protein expression had a significantly better overall survival. The biological role of BCL6 in translocated cases where repression of known target genes is not demonstrated is intriguing and warrants further investigation.
Collapse
Affiliation(s)
- J Iqbal
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - TC Greiner
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - K Patel
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - BJ Dave
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - L Smith
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - J Ji
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - G Wright
- Metabolism Branch and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - WG Sanger
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - DL Pickering
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - S Jain
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - DE Horsman
- Departments of Pathology and British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Y Shen
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - K Fu
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - DD Weisenburger
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - CP Hans
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - E Campo
- Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - RD Gascoyne
- Departments of Pathology and British Columbia Cancer Agency, Vancouver, BC, Canada
| | - A Rosenwald
- Department of Pathology, University of Würzburg, Würzburg, Germany
| | - ES Jaffe
- Metabolism Branch and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - J Delabie
- Norwegian Radium Hospital, Oslo, Norway
| | - L Rimsza
- Department of Pathology, University of Arizona, Tucson, Arizona, USA
| | - G Ott
- Department of Pathology, University of Würzburg, Würzburg, Germany
| | | | - JM Connors
- Departments of Pathology and British Columbia Cancer Agency, Vancouver, BC, Canada
| | - JM Vose
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - T McKeithan
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - LM Staudt
- Metabolism Branch and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - WC Chan
- Departments of Pathology and Microbiology, Pediatrics, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | | |
Collapse
|
37
|
Hammer AS, Williams B, Dietz HH, Hamilton-Dutoit SJ. High-throughput immunophenotyping of 43 ferret lymphomas using tissue microarray technology. Vet Pathol 2007; 44:196-203. [PMID: 17317796 DOI: 10.1354/vp.44-2-196] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
To validate the use of the tissue microarray (TMA) method for immunophenotyping of ferret lymphomas, a TMA was constructed containing duplicate 1-mm cores sampled from 112 paraffin-embedded lymphoma tissue specimens obtained from 43 ferret lymphoma cases. Immunohistochemical (IHC) expression of CD3, CD79alpha, and Ki-67 (MIB-1) was determined by TMA and whole mount (WM) staining of each individual case for result comparison. There was a high correlation between CD79alpha and CD3 results comparing ferret TMA and WM sections (kappa statistic 0.71-0.73 for single-core TMA and 0.79-0.95 for duplicate-core TMA) and between continuous data from Ki-67 staining of ferret TMA sections and WM sections (concordance correlation coefficients 0.77 for single cores and 0.87 for duplicate cores). Subsequently, a panel of commercially available antibodies was applied to the TMA for the analysis of expression in ferret lymphomas. The results of this study confirmed previously published results suggesting specific cross-reactivity of the applied IHC markers (CD3, CD79alpha, Ki67) with ferret lymphoma tissue. Other IHC markers (CD45Ro, bcl2, bcl10, MUM1, CD30, vimentin) were also expressed in subsets of the included ferret lymphomas. Further studies are necessary to determine the usefulness of these markers for diagnostic and prognostic evaluation of ferret lymphomas. In conclusion, the TMA technology was useful for rapid and accurate analysis of protein expression in large archival cohorts of ferret lymphoma cases.
Collapse
Affiliation(s)
- A S Hammer
- Department of Poultry Fish and Fur Animals, The Danish Institute for Food and Veterinary Research, Aarhus, Denmark.
| | | | | | | |
Collapse
|
38
|
Abstract
Molecular profiling, the classification of tissue or other specimens for diagnostic, prognostic, and predictive purposes based on multiple gene expression, is a technology that holds major promise for optimizing the management of patients with cancer. However, the use of these tests for clinical decision making presents many challenges to overcome. Assay development and data analysis in this field have been largely exploratory, and leave numerous possibilities for the introduction of bias. Standardization of profiles remains the exception. Classifier performance is usually overinterpreted by presenting the results as p-values or multiplicative effects (e.g., relative risks), while the absolute sensitivity and specificity of classification remain modest at best, especially when tested in large validation samples. Validation has often been done with suboptimal attention to methodology and protection from bias. The postulated classifier performance may be inflated compared to what these profiles can achieve. With the exception of breast cancer, we have little evidence about the incremental discrimination that molecular profiles can provide versus classic risk factors alone. Clinical trials have started to evaluate the utility of using molecular profiles for breast cancer management. Until we obtain data from these trials, the impact of these tests and the net benefit under real-life settings remain unknown. Optimal incorporation into clinical practice is not straightforward. Finally, cost-effectiveness is difficult to appreciate until these other challenges are addressed. Overall, molecular profiling is a fascinating and promising technology, but its incorporation into clinical decision making requires careful planning and robust evidence.
Collapse
Affiliation(s)
- John P A Ioannidis
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
| |
Collapse
|
39
|
Taylor CR. Quantifiable internal reference standards for immunohistochemistry: the measurement of quantity by weight. Appl Immunohistochem Mol Morphol 2006; 14:253-9. [PMID: 16932014 DOI: 10.1097/00129039-200609000-00001] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Zlobec I, Steele R, Michel RP, Compton CC, Lugli A, Jass JR. Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol 2006; 19:1236-42. [PMID: 16741523 DOI: 10.1038/modpathol.3800642] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Molecular tumor markers are often studied in colorectal cancer using immunohistochemistry to determine their prognostic or predictive value. Protein expression is typically assigned a 'positive' score based on a predetermined cutoff. A semiquantitative scoring method that evaluates the percentage of positive tumor cells (0-100%) may provide a better understanding of the prognostic or predictive significance of these markers. The aim of this study was to assess and compare the interobserver agreement of immunohistochemistry scores using a percentage scoring method and three categorical scoring systems. Immunohistochemistry for p53, Bcl-2, vascular endothelial growth factor (VEGF) and apoptotic protease activating factor-1 (APAF-1) was performed on 87 tumor biopsies from patients with rectal carcinoma and scored independently by four pathologists as the percentage of positive tumor cells. Interobserver agreement was assessed by the intraclass correlation coefficient. The intraclass correlation coefficients for p53 and VEGF (>0.6) indicate substantial agreement between observers. The distribution of Bcl-2 and APAF-1 scores in addition to weaker interobserver agreement by percentage scoring suggest that this approach may not be appropriate for these proteins. In conclusion, p53 and VEGF protein expression assessed by immunohistochemistry in colorectal cancer and scored as a percentage of positive tumor cells may be a viable alternative scoring method.
Collapse
Affiliation(s)
- Inti Zlobec
- Department of Pathology, McGill University, Montreal, QC, Canada.
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
The landmark sequencing of the human genome has ushered in a new field of large-scale research. Advances in understanding the molecular basis of disease have opened up new opportunities to develop genomics-based tools to diagnose, predict disease onset or recurrence, tailor treatment options, and assess treatment response. Although still in the early stages of research and development, genomic biomarker research has the capability of providing a comprehensive insight into pathophysiological processes as well as more precise predictors of outcome not previously attainable with traditional biomarkers. Before genomic biomarkers are incorporated into clinical practice, several issues will need to be addressed in order to generate the necessary levels of evidence to demonstrate analytical and clinical validity and utility. In addition, efforts will be needed to educate health professionals and the public about genomics-based tools, revise regulatory oversight mechanisms, and ensure privacy safeguards of the information generated from these new tests.
Collapse
Affiliation(s)
- Geoffrey S Ginsburg
- Center for Genomic Medicine, Institute for Genome Sciences & Policy, Duke University, Box 3382, Durham, NC 27708, USA.
| | | |
Collapse
|
42
|
Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, Müller-Hermelink HK, Delabie J, Jaffe ES, Grogan TM, Connors JM, Vose JM, Armitage JO, Staudt LM, Chan WC. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:961-8. [PMID: 16418494 DOI: 10.1200/jco.2005.03.4264] [Citation(s) in RCA: 231] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The role of BCL2 as a predictor of survival in diffuse large B-cell lymphoma (DLBCL) is controversial. DLBCL is heterogeneous, and the expression of BCL2 is variable within the two major subgroups of DLBCL, germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL, as well as primary mediastinal DLBCL. PATIENTS AND METHODS In this study, we investigated the correlation of BCL2 expression with survival in the two major subgroups of DLBCL, as well as the mechanisms of BCL2 expression. RESULTS There was no significant correlation between BCL2 protein expression and overall survival within the GCB subgroup, but BCL2 expression had a significant adverse effect on overall survival within the ABC subgroup (P = .008). This correlation was also observed at the mRNA level (P < .04). The difference remained significant when the analyses were performed at different cutoff values. The t(14;18) was frequently observed in the GCB subgroup and was highly associated with BCL2 expression. Patients with ABC DLBCL did not exhibit t(14;18) but had a markedly higher frequency of chromosome 18q21 amplification, on which BCL2 resides. Thus, alternative mechanisms such as 18q21 amplification or activation of the nuclear factor-kappa B pathway, as reported previously, seem to be mainly responsible for the upregulation of BCL2 expression in the ABC subgroup. CONCLUSION Treating all DLBCL as a single entity ignores the mechanistic differences in BCL2 upregulation and obscures the prognostic significance of BCL2 expression. Hence, the significance of BCL2 and other biomarkers should be assessed in the context of DLBCL subgroups in future studies.
Collapse
MESH Headings
- Aged
- Biomarkers, Tumor/analysis
- Chromosomes, Human, Pair 18
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- Lymphoma, B-Cell/chemistry
- Lymphoma, Large B-Cell, Diffuse/chemistry
- Male
- Middle Aged
- Oligonucleotide Array Sequence Analysis
- Predictive Value of Tests
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/analysis
- RNA, Messenger/analysis
- RNA, Neoplasm/analysis
- Survival Analysis
- Translocation, Genetic
- Up-Regulation
Collapse
Affiliation(s)
- Javeed Iqbal
- Leukemia/Lymphoma Molecular Profiling Project, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|